Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
NCI-2009-01564 ( Registry Identifier: NCI's CTRP )
09-005736 ( Other Identifier: Mayo Clinic IRB )
MC0985 ( Other Identifier: Mayo Clinic Cancer Center )
X05306 ( Other Identifier: MPI Protocol )